Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Recent estimates suggest that >300 million people are afflicted by serious fungal infections worldwide. Current antifungal drugs are static and toxic and/or have a narrow spectrum of activity. Thus, there is an urgent need for the development of new antifungal drugs. The fungal sphingolipid glucosylceramide (GlcCer) is critical in promoting virulence of a variety of human-pathogenic fungi. In this study, we screened a synthetic drug library for compounds that target the synthesis of fungal, but not mammalian, GlcCer and found two compounds [ N ′-(3-bromo-4-hydroxybenzylidene)-2-methylbenzohydrazide (BHBM) and its derivative, 3-bromo- N ′-(3-bromo-4-hydroxybenzylidene) benzohydrazide (D0)] that were highly effective in vitro and in vivo against several pathogenic fungi. BHBM and D0 were well tolerated in animals and are highly synergistic or additive to current antifungals. BHBM and D0 significantly affected fungal cell morphology and resulted in the accumulation of intracellular vesicles. Deep-sequencing analysis of drug-resistant mutants revealed that four protein products, encoded by genes APL5 , COS111 , MKK1 , and STE2 , which are involved in vesicular transport and cell cycle progression, are targeted by BHBM. IMPORTANCE Fungal infections are a significant cause of morbidity and mortality worldwide. Current antifungal drugs suffer from various drawbacks, including toxicity, drug resistance, and narrow spectrum of activity. In this study, we have demonstrated that pharmaceutical inhibition of fungal glucosylceramide presents a new opportunity to treat cryptococcosis and various other fungal infections. In addition to being effective against pathogenic fungi, the compounds discovered in this study were well tolerated by animals and additive to current antifungals. These findings suggest that these drugs might pave the way for the development of a new class of antifungals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Nonfilamentous C. albicans Mutants Are Avirulent
Lo, H.-J., Köhler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., & Fink, G. R. (1997) · Cell · doi:10.1016/s0092-8674(00)80358-x · Cited by 1,809
Schuldiner, M., Collins, S. R., Thompson, N. J., Denic, V., Bhamidipati, A., Punna, T., Ihmels, J., Andrews, B., Boone, C., Greenblatt, J. F., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.031 · Cited by 870 · cited 1×
“Furthermore, the APL5 protein directly interacts with the VPS3 and GOS1-encoded proteins, which were identified by the HIP-HOP assay (46, 47).”
BackgroundNoble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134 · cited 2×
“and interact with other drugs such as chemotherapy agents and immunosuppressants (4).”
BackgroundKechichian, T. B., Shea, J., & Del Poeta, M. (2007) · Infection and Immunity · doi:10.1128/iai.00587-07 · Cited by 128 · cited 1×
“neoformans is able to survive and replicate inside macrophages (37), and replication inside nonactivated macrophages is an important factor in its pathogenicity (38).”
BackgroundSingh, A., Wang, H., Silva, L. C., Na, C., Prieto, M., Futerman, A. H., Luberto, C., & Del Poeta, M. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2011.01735.x · Cited by 81
Self-citationKnocking out multigene redundancies via cycles of sexual assortment and fluorescence selection
Suzuki, Y., Onge, R. P. S., Mani, R., King, O. D., Heilbut, A., Labunskyy, V. M., Chen, W., Pham, L., Zhang, L. V., Tong, A. H. Y., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1550 · Cited by 78 · cited 1×
“cerevisiae RYO0622 strain was used for the generation of mutants (23).”
BackgroundSelf-citation
Cited by
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 445
Self-citationTreatment strategies for cryptococcal infection: challenges, advances and future outlook
Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00511-0 · Cited by 363
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Self-citation
Metadata
- Authors
- Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., Ashbaugh, A., Linke, M. J., Cushion, M., Collins, M., Ananthula, H. K., Sallans, L., Desai, P. B., Wiederhold, N. P., Fothergill, A. W., Kirkpatrick, W. R., Patterson, T., Wong, L. H., Sinha, S., Giaever, G., Nislow, C., Flaherty, P., Pan, X., Cesar, G. V., de Melo Tavares, P., Frases, S., Miranda, K., Rodrigues, M. L., Luberto, C., Nimrichter, L., & Del Poeta, M.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2015-07
- Volume
- 6
- Issue
- 3
- Pages
- e00647-e00647
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- OpenAlex
- W2142269012
- Cited by
- 144
- References
- 9
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids. https://app.cochat.ai/papers/10.1128/mbio.00647-15
- The paper
- Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., Ashbaugh, A., Linke, M. J., Cushion, M., Collins, M., Ananthula, H. K., Sallans, L., Desai, P. B., Wiederhold, N. P., Fothergill, A. W., . . . Del Poeta, M. (2015). Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids. mBio. https://doi.org/10.1128/mbio.00647-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.